Literature DB >> 32369409

Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy.

Mary-Elizabeth M Percival1,2,3, Ryan C Lynch1,3,4, Anna B Halpern1,2,3, Mazyar Shadman1,3,4, Ryan D Cassaday1,2,3, Chaitra Ujjani1,3,4, Andrei Shustov1,2,4, Yolanda D Tseng1,3,5, Catherine Liu1,3,6,7, Steven Pergam1,3,6,7, Edward N Libby1,3,4, Bart L Scott1,3,4, Stephen D Smith1,3,4, Damian J Green1,3,4, Ajay K Gopal1,3,4, Andrew J Cowan1,3,4.   

Abstract

In January 2020, the first documented patient in the United States infected with severe acute respiratory syndrome coronavirus 2 was diagnosed in Washington State. Since that time, community spread of coronavirus disease 2019 (COVID-19) in the state has changed the practice of oncologic care at our comprehensive cancer center in Seattle. At the Seattle Cancer Care Alliance, the primary oncology clinic for the University of Washington/Fred Hutchinson Cancer Consortium, our specialists who manage adult patients with hematologic malignancies have rapidly adjusted clinical practices to mitigate the potential risks of COVID-19 to our patients. We suggest that our general management decisions and modifications in Seattle are broadly applicable to patients with hematologic malignancies. Despite a rapidly changing environment that necessitates opinion-based care, we provide recommendations that are based on best available data from clinical trials and collective knowledge of disease states.

Entities:  

Mesh:

Year:  2020        PMID: 32369409      PMCID: PMC7489485          DOI: 10.1200/OP.20.00241

Source DB:  PubMed          Journal:  JCO Oncol Pract        ISSN: 2688-1527


  47 in total

1.  Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group.

Authors:  Josep-Maria Ribera; Olga García; Albert Oriol; Cristina Gil; Pau Montesinos; Teresa Bernal; José González-Campos; Esperanza Lavilla; Jordi Ribera; Salut Brunet; María-Pilar Martínez; Mar Tormo; Eulàlia Genescà; Pere Barba; Josep Sarrà; María-Carmen Monteserín; Beatriz Soria; Mercedes Colorado; Antònia Cladera; Antoni García-Guiñón; María Calbacho; Alfons Serrano; Xavier Ortín; María Pedreño; Maria-Luz Amigo; Lourdes Escoda; Evarist Feliu
Journal:  Leuk Res       Date:  2015-12-02       Impact factor: 3.156

Review 2.  Immune defects in patients with chronic lymphocytic leukemia.

Authors:  Farhad Ravandi; Susan O'Brien
Journal:  Cancer Immunol Immunother       Date:  2005-07-16       Impact factor: 6.968

3.  Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.

Authors:  Gerwin Huls; Dana A Chitu; Violaine Havelange; Mojca Jongen-Lavrencic; Arjan A van de Loosdrecht; Bart J Biemond; Harm Sinnige; Beata Hodossy; Carlos Graux; Rien van Marwijk Kooy; Okke de Weerdt; Dimitri Breems; Saskia Klein; Jürgen Kuball; Dries Deeren; Wim Terpstra; Marie-Christiane Vekemans; Gert J Ossenkoppele; Edo Vellenga; Bob Löwenberg
Journal:  Blood       Date:  2019-01-10       Impact factor: 22.113

4.  4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial.

Authors:  Peter J Hoskin; Amy A Kirkwood; Bilyana Popova; Paul Smith; Martin Robinson; Eve Gallop-Evans; Stewart Coltart; Timothy Illidge; Krishnaswamy Madhavan; Caroline Brammer; Patricia Diez; Andrew Jack; Isabel Syndikus
Journal:  Lancet Oncol       Date:  2014-02-24       Impact factor: 41.316

5.  The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.

Authors:  Andrew M Evens; Fangxin Hong; Leo I Gordon; Richard I Fisher; Nancy L Bartlett; Joseph M Connors; Randy D Gascoyne; Henry Wagner; Mary Gospodarowicz; Bruce D Cheson; Patrick J Stiff; Ranjana Advani; Thomas P Miller; Richard T Hoppe; Brad S Kahl; Sandra J Horning
Journal:  Br J Haematol       Date:  2013-01-29       Impact factor: 6.998

6.  Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.

Authors:  Sarah Bertoli; Emilie Bérard; Françoise Huguet; Anne Huynh; Suzanne Tavitian; François Vergez; Sophie Dobbelstein; Nicole Dastugue; Véronique Mansat-De Mas; Eric Delabesse; Eliane Duchayne; Cécile Demur; Audrey Sarry; Valérie Lauwers-Cances; Guy Laurent; Michel Attal; Christian Récher
Journal:  Blood       Date:  2013-01-30       Impact factor: 22.113

7.  Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.

Authors:  Moshe Mittelman; Uwe Platzbecker; Boris Afanasyev; Sebastian Grosicki; Raymond S M Wong; Achilles Anagnostopoulos; Benjamin Brenner; Claudio Denzlinger; Giuseppe Rossi; Arnon Nagler; Regina Garcia-Delgado; Maria Socorro O Portella; Zewen Zhu; Dominik Selleslag
Journal:  Lancet Haematol       Date:  2017-12-11       Impact factor: 18.959

8.  Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.

Authors:  David J Straus; Monika Długosz-Danecka; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Tatyana Feldman; Piotr Smolewski; Kerry J Savage; Nancy L Bartlett; Jan Walewski; Radhakrishnan Ramchandren; Pier Luigi Zinzani; Martin Hutchings; Joseph M Connors; John Radford; Javier Munoz; Won Seog Kim; Ranjana Advani; Stephen M Ansell; Anas Younes; Harry Miao; Rachael Liu; Keenan Fenton; Andres Forero-Torres; Andrea Gallamini
Journal:  Blood       Date:  2020-03-05       Impact factor: 22.113

9.  Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.

Authors:  Elias J Jabbour; Nicola Gökbuget; Hagop M Kantarjian; Xavier Thomas; Richard A Larson; Sung-Soo Yoon; Armin Ghobadi; Max S Topp; Qui Tran; Janet L Franklin; Stephen J Forman; Anthony S Stein
Journal:  Cancer       Date:  2019-08-21       Impact factor: 6.860

10.  AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.

Authors:  John P Leonard; Marek Trneny; Koji Izutsu; Nathan H Fowler; Xiaonan Hong; Jun Zhu; Huilai Zhang; Fritz Offner; Adriana Scheliga; Grzegorz S Nowakowski; Antonio Pinto; Francesca Re; Laura Maria Fogliatto; Phillip Scheinberg; Ian W Flinn; Claudia Moreira; José Cabeçadas; David Liu; Stacey Kalambakas; Pierre Fustier; Chengqing Wu; John G Gribben
Journal:  J Clin Oncol       Date:  2019-03-21       Impact factor: 44.544

View more
  8 in total

Review 1.  Cancer or COVID-19? A Review of Guidelines for Safe Cancer Care in the Wake of the Pandemic.

Authors:  Manit K Gundavda; Kaival K Gundavda
Journal:  SN Compr Clin Med       Date:  2020-11-21

Review 2.  SARS-CoV-2 testing for asymptomatic adult cancer patients before initiating systemic treatments: a systematic review.

Authors:  Guilherme Haradaa; Fernanda F Antonacio; Aline Bl Gongora; Marina H Behar; Fernanda C Capareli; Diogo A Bastos; Rodrigo R Munhoz; Frederico P Costa; Denis L Jardim; Celso Arrais-Rodrigues; Yana Novis; Artur Katz; Gilberto de Castro Junior
Journal:  Ecancermedicalscience       Date:  2020-09-09

3.  The Impact of COVID-19 on Cancer Care in the Post Pandemic World: Five Major Lessons Learnt from Challenges and Countermeasures of Major Asian Cancer Centres.

Authors:  Laureline Gatellier; Abhishek Shankar; Luh K Mela Dewi; Quazi Mushtaq Hussain; Tashi Dendup Wangdi; Dato Babu Sukumaran; Nina Kemala Sari; Sahar Tavakkoli Shiraji; Mohammad Biglari; Mamak Tahmasebi; Satoshi Iwata; Tatsuya Suzuki; Seung-Kwon Myung; June Young Chun; Jong Soo Han; Fen Nee Lau; Suhana Yusak; Luvsandorj Bayarsaikhan; Khin Thin Mu; Kishore K Pradhananga; Aasim Yusuf; Ching-Hung Lin; Ruru Chun-Ju Chiang; Suleeporn Sangrajran; Quang Tien Nguyen; Giang Nguyen Huong; Aung Naing Soe; D N Sharma; Manju Sengar; C S Pramesh; Tomohiro Matsuda; Alireza Mosavi Jarrahi; William Hwang
Journal:  Asian Pac J Cancer Prev       Date:  2021-03-01

4.  Favourable outcomes for young lymphoma patients but age-old problems persist.

Authors:  Dr Praveen Gounder; Prof Judith Trotman
Journal:  EClinicalMedicine       Date:  2020-11-05

Review 5.  COVID-19: The Impact in Oncology Care.

Authors:  Upasana Ray; Faisal Aziz; Abhishek Shankar; Aalekhya Sharma Biswas; Abhijit Chakraborty
Journal:  SN Compr Clin Med       Date:  2020-10-23

6.  Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy.

Authors:  Tarun Sahu; Henu Kumar Verma; Bhaskar Lvks
Journal:  World J Virol       Date:  2022-07-25

7.  Saudi Lymphoma Group's Clinical Practice Guidelines for Diagnosis, Management and Follow-up of Patients with Various Types of Lymphoma during the Coronavirus Disease 2019 Pandemic.

Authors:  Musa Alzahrani; Mubarak M Al-Mansour; John Apostolidis; Ahmed Barefah; Reyad Dada; Ayman Alhejazi; Yasir Alayed; Ibraheem Motabi; Mansoor Radwi; Hani Al-Hashmi
Journal:  Saudi J Med Med Sci       Date:  2020-08-20

8.  Reduced bendamustine for elderly patients with follicular lymphoma.

Authors:  Yosuke Masamoto; Arika Shimura; Mineo Kurokawa
Journal:  Ann Hematol       Date:  2021-06-21       Impact factor: 3.673

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.